Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Is the Growth Rate of the AL Amyloidosis Market?

Over the past few years, the AL amyloidosis market has seen notable expansion. Its size is expected to surge from $3.11 billion in 2024 to $3.52 billion in 2025, with a compound annual growth rate (CAGR) of 13.2%. The significant growth during the historical period could be linked to heightened consciousness about AL amyloidosis among healthcare providers, a surge in cases of AL amyloidosis, increasing numbers in the elderly populace, an increase in diagnostic centers, and advancements in cardiac imaging.

What Growth Rate Is Forecasted for the AL Amyloidosis Market by 2029?

The market size for AL amyloidosis is anticipated to experience significant expansion in the coming years. Predictions indicate that it will rise to $5.74 billion by 2029, with a compound annual growth rate (CAGR) of 13.0%. The anticipated growth during the forecast period can be associated with several factors including an increase in diagnosed mutations in blood cell DNA, improvements in healthcare infrastructure, a rising influence of multiple myeloma, the advent of combined treatments, and a heightened reliance on high-dose chemotherapy. Key trends expected in the forecast period encompass progress in diagnostic methods, breakthroughs in drug delivery technology, advancements in blood testing, the emergence of targeted treatments, and the integration of artificial intelligence(AI) in diagnostic processes.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=20710&type=smp

Which Key Companies Are Shaping the Future of the AL Amyloidosis Market?

Major companies operating in the AL amyloidosis market are Johnson & Johnson, AbbVie Inc., Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca PLC, Takeda Pharmaceutical Company Limited, Boehringer Ingelheim International GmbH, Astellas Pharma Inc., Genmab A/S, Alexion Pharmaceuticals Inc., Alnylam Pharmaceuticals Inc., Prothena Corporation plc, BridgeBio Pharma Inc., Sorrento Therapeutics Inc., Ionis Pharmaceuticals Inc., Ultromics Ltd, Neurimmune AG, Immix Biopharma Inc., Oncopeptides AB, Attralus Inc.

Which Factors Are Driving Demand in the AL Amyloidosis Industry?

The growth of the AL amyloidosis market can be attributed to the increasing prevalence of plasma cell disorders. Conditions in which abnormal plasma cells excessively produce abnormal antibodies potentially lead to organ damage, and these are referred to as plasma cell disorders. A progressively aging population, advancements in diagnostic technologies, and an increase in life expectancy are thought to be the reasons for the upward trend in plasma cell disorders. These disorders are the cause of AL amyloidosis, specifically the excessive production of light chain proteins that are abnormal. The result is the buildup of amyloid deposits in tissues and organs, intensifying the impact of plasma cell abnormalities. The American Cancer Society, a nonprofit organization based in the US, reported in August 2024 that an estimated 35,780 new cases of multiple myeloma (19,520 men and 16,260 women) would be diagnosed in 2024. Additionally, there will be approximately 12,540 fatalities (7,020 men and 5,520 women). Therefore, the AL amyloidosis market surge is due to the increased prevalence of plasma cell disorders.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=20710&type=smp

How Is the AL Amyloidosis Market Segmented by Several Divisions?

The AL amyloidosis market covered in this report is segmented –

1) By Treatment: Chemotherapy, Supportive Care, Surgery, Stem Cell Transplant, Targeted Therapy

2) By Drugs: Transthyretin Transport Inhibitor, Immunomodulatory Drugs, Monoclonal Antibodies, Proteasome Inhibitors, Other Drugs

3) By Route Of Administration: Intravenous, Oral

4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

Subsegments:

1) By Chemotherapy: Conventional Chemotherapy Agents, High-Dose Chemotherapy

2) By Supportive Care: Pain Management, Organ-specific Supportive Care (Cardiac, Renal)

3) By Surgery: Organ Transplantation, Debulking Surgery

4) By Stem Cell Transplant: Autologous Stem Cell Transplant, Allogeneic Stem Cell Transplant

5) By Targeted Therapy: Monoclonal Antibodies, Proteasome Inhibitors, Kinase Inhibitors

What are the Emerging Market Trends Driving the Growth of the AL Amyloidosis Industry?

In order to enhance treatment efficiency and patient results, leading companies in the AL amyloidosis market are prioritizing the creation of innovative therapies like next-generation B-cell maturation antigen (BCMA)-directed CAR T-cell therapy. This therapy is a progressive version of immunotherapy where a patient’s T cells are modified to target and eradicate BCMA on the cancer cells’ surface, particularly in multiple myeloma. For example, Immix Biopharma Inc., a biopharmaceutical enterprise based in the United States, earned the U.S. Food and Drug Administration’s (FDA) consent in September 2023 to use NXC-201 for treating the deadly blood disorder Amyloid Light Chain (AL) Amyloidosis. NXC-201 is a new CAR-T cell therapy that’s currently being assessed in clinical examinations for AL amyloidosis treatment, and it has demonstrated impressive results with a 100% hematologic response rate, as well as enhancements in organ function in patients who had not benefited from prior treatments.

Access The Full Report Here:

https://www.thebusinessresearchcompany.com/report/al-amyloidosis-global-market-report

Which Regions Are Driving Growth in the AL Amyloidosis Market?

North America was the largest region in the AL amyloidosis market in 2024. The regions covered in the AL amyloidosis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase The Full Report Today:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=20710

This Report Delivers Insight On:

1. How big is the al amyloidosis market, and how is it changing globally?

2. Who are the major companies in the al amyloidosis market, and how are they performing?

3. What are the key opportunities and risks in the al amyloidosis market right now?

4. Which products or customer segments are growing the most in the al amyloidosis market?

5. What factors are helping or slowing down the growth of the al amyloidosis market?

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Europe +44 7882 955267

Asia & Others +44 7882 955267 & +91 8897263534

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model